$ACXP

Acurx Pharmaceuticals, Inc. (ACXP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. At the close of business on August 20, 2026, the record date of the Annual Meeting of Stockholders of Acurx Pharmaceuticals, Inc. (the “Company”) held on October 16, 2026 (the “Annual Meeting”), there were 5,471,297 s

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

Acurx Pharmaceuticals (NASDAQ: ACXP) reported Q2 2026 results for the quarter ended June 30, 2026. It raised about $2.5M via a registered direct offering at $3.03/share and $0.8M under an equity line. Cash rose to $10.7M. R&D was $1.1M, G&A $1.2M, and net loss was $2.3M ($0.53/share).

Acurx Pharmaceuticals (ACXP) has experienced significant price volatility, including a 1-for-20 reverse stock split in August 2025, as it continues to develop antibiotic candidates for difficult infections. The company, a clinical-stage biopharmaceutical firm, focuses on novel antibiotics, with its lead candidate targeting Clostridioides difficile infection (CDI). As a development-stage company, its valuation is primarily driven by clinical milestones, regulatory progress, and financing activities rather than current earnings.

Acurx Pharmaceuticals (ACXP) reported a Q1 2026 net loss of $1.7 million, narrowing from $2.1 million, with cash increasing to $9.3 million. The company is advancing its ibezapolstat program for C. difficile, initiating a Phase 2 trial for recurrent CDI and strengthening its patent portfolio. Despite operational progress, the stock experienced a mild negative market reaction, continuing a historical pattern of post-earnings declines.

Joseph C. Scodari, a director at Acurx Pharmaceuticals (ACXP), has been granted 2,150 stock options as compensation for his board service. The options have an exercise price of $2.36 per share, will fully vest on April 20, 2027, and are set to expire on April 20, 2036. This grant reflects a compensation award rather than a market purchase or sale of shares.

Acurx Pharmaceuticals (NASDAQ:ACXP) announced a direct offering of 825,085 shares of common stock at $3.03 per share, aiming to raise approximately $2.5 million before expenses. Concurrently, it will issue unregistered short-term warrants that could generate an additional $4.6 million if fully exercised. The company plans to use the net proceeds for working capital and general corporate purposes, with analysts maintaining optimistic price targets.

Acurx Pharmaceuticals (NASDAQ: ACXP) will report its full year and fourth quarter 2025 financial results on Friday, March 13, 2026, at 8:00 a.m. ET, before U.S. markets open. Management, including CEO David P. Luci and CFO Robert G. Shawah, will host a conference call to discuss the results and provide a business update. The company's lead antibiotic candidate, Ibezapolstat, is preparing for international Phase 3 clinical trials for C. difficile Infection (CDI) and has received positive regulatory guidance from both the EMA and FDA.

Shares of Confluent Inc ( NASDAQ:CFLT ) rose sharply in pre-market trading. Confluent is exploring a sale after attracting acquisition interest from tech firms and private equity investors, according to Reuters. Confluent shares jumped 19.5% to $24.77 in the pre-market trading session.

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.